Why is pregnancy sickness drug not easily accessible to all?

Linzi Kinghorn investigates the barriers preventing universal access to a drug that effectively treats pregnancy sickness through the NHS. The drug, which has shown significant relief for many women, faces limitations due to various factors including cost, availability, and regulatory hurdles. This situation highlights the broader issue of healthcare resource allocation and the challenges in ensuring that all expectant mothers receive the necessary medical support. The lack of accessibility raises important questions about healthcare equity and the prioritization of treatments within public health systems.